[1]但丹 陈凤霞 嘉颖 浦飞飞.信号转导和转录活化因子3在骨肉瘤中的表达及临床意义[J].中国中医骨伤科杂志,2025,33(02):29-33.[doi:10.20085/j.cnki.issn1005-0205.250206]
　DAN Dan,CHEN Fengxia,JIA Ying,et al.Expression and Clinical Significance of Signal Transduction and Transcriptional Activation Factor 3 in Osteosarcoma[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2025,33(02):29-33.[doi:10.20085/j.cnki.issn1005-0205.250206]
点击复制

信号转导和转录活化因子3在骨肉瘤中的表达及临床意义()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第33卷
期数:
2025年02期
页码:
29-33
栏目:
临床研究
出版日期:
2025-02-15

文章信息/Info

Title:
Expression and Clinical Significance of Signal Transduction and Transcriptional Activation Factor 3 in Osteosarcoma
文章编号:
1005-0205(2025)02-0029-05
作者:
但丹 陈凤霞 嘉颖 浦飞飞
1武汉市第一医院(武汉,430022)
2武汉大学中南医院
3华中科技大学同济医学院第一临床学院
Author(s):
DAN Dan1; CHEN Fengxia2; JIA Ying3; PU Feifei1△
1Wuhan No.1 Hospital,Wuhan 430022,China; 2Zhongnan Hospital of Wuhan University,Wuhan 430071,China; 3The First Clinical School,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China.
关键词:
骨肉瘤;  信号转导和转录活化因子3;  免疫组织化学法;  生存分析;  临床预后
Keywords:
osteosarcoma;  signal transduction and transcri-ptional activation factor 3;  immunohistochemical method;  survival analysis;  clinical prognosis
分类号:
R738.1
DOI:
10.20085/j.cnki.issn1005-0205.250206
文献标志码:
A
摘要:
目的:探讨骨肉瘤中信号转导和转录活化因子3(STAT3)蛋白表达水平及临床意义。方法:用免疫组织化学法检测36例骨肉瘤标本中STAT3蛋白表达水平,分析STAT3表达水平与患者临床病理特征的相关性。采用Kaplan-Meier生存分析探讨STAT3表达水平与骨肉瘤患者预后的相关性。结果:STAT3蛋白阳性反应主要定位于细胞质,36例骨肉瘤肿瘤组织中STAT3高表达31例(86.11%),癌旁组织中STAT3高表达13例(36.11%),差异有统计学意义(P<0.05); STAT3高表达与患者Enneking分期高、化疗反应较差、肺转移发生率高、总生存期短相关,差异有统计学意义(P<0.05)。结论:STAT3在骨肉瘤中高表达,其表达强度与患者不良预后正相关。
Abstract:
Objective:To investigate the expression and its clinical significance of signal transduction and transcriptional activating factor 3(STAT3)protein in osteosarcoma.Methods:The expression of STAT3 protein in 36 osteosarcoma samples was detected by immunohistochemistry,and the clinicopathological features of the patients were analyzed.Kaplan-Meier survival analysis was used to investigate the correlation between STAT3 expression and prognosis of patients with osteosarcoma.Results:The positive reaction of STAT3 protein was mainly located in cytoplasm.STAT3 was overexpressed in 31 cases(86.11%)and 13 cases(36.11%)of 36 cases of osteosarcoma(P<0.05).Patients with high STAT3 expression had high Enneking stages,poor chemotherapy response,high incidence of lung metastasis and short overall survival(P<0.05).Conclusion:STAT3 protein is highly expressed in osteosarcoma,and its expression intensity is positively correlated with poor prognosis.

参考文献/References:

[1] YAO Y,WANG D,ZHENG L,et al.Advances in prognostic models for osteosarcoma risk[J].Heliyon,2024,10(7):e28493.
[2] 吴蔚,景豆豆,曹理,等.骨肉瘤免疫治疗的现状和前景[J].肿瘤防治研究,2022,49(7):721-726.
[3] 董帅,梁海生,畅磊,等.STAT3在电离辐射响应、肿瘤发展以及组织修复中的作用[J].中华放射医学与防护杂志,2022,42(9):722-726.
[4] LIU Y,LIAO S,BENNETT S,et al.STAT3 and its targeting inhibitors in osteosarcoma[J].Cell Prolif,2021,54(2):e12974.
[5] 钟彬龙,邵增务.STAT3在骨肉瘤中的研究进展[J].华中科技大学学报(医学版),2021,50(3):398-403.
[6] MIAO J,CHEN S,CAO H,et al.Bruceantinol targeting STAT3 exerts promising antitumor effects in in vitro and in vivo osteosarcoma models[J].Mol Carcinog,2024,63(6):1133-1145.
[7] 中国医师协会骨科医师分会骨肿瘤专业委员会.骨肉瘤临床循证指南[J].中华骨与关节外科杂志,2018,11(4):288-301.
[8] LI X,LIU J.FANCD2 inhibits ferroptosis by regulating the JAK2/STAT3 pathway in osteosarcoma[J].BMC Cancer,2023,23(1):179.
[9] DUAN X L,GUO J P,LI F,et al.Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice[J].Future Oncol,2020,16(24):1815-1824.
[10] OI T,ASANUMA K,MATSUMINE A,et al.STAT3 inhibitor,cucurbitacin Ⅰ,is a novel therapeutic agent for osteosarcoma[J].Int J Oncol,2016,49(6):2275-2284.
[11] 杨锴,王亚莉,杨建萍,等.骨肉瘤和良性骨肿瘤中PIM-3和p-STAT3蛋白表达的相关性及临床病理意义[J].中国实用医刊,2012,39(14):73-75.
[12] WANG X,DING R,FU Z,et al.Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells[J].Front Pharmacol,2024,15:1303732.
[13] PARK G B,KIM D J,KIM Y S,et al.Silencing of galectin-3 represses osteosarcoma cell migration and invasion through inhibition of FAK/Src/Lyn activation and β-catenin expression and increases susceptibility to chemotherapeutic agents[J].Int J Oncol,2015,46(1):185-194.
[14] LIN M C,CHEN G Y,YU H H,et al.Repurposing the diuretic benzamil as an anti-osteosarcoma agent that acts by suppressing integrin/FAK/STAT3 signalling and compromising mitochondrial function[J].Bone Joint Res,2024,13(4):157-168.
[15] CHU Y,NAYYAR G,JIANG S,et al.Combinatorial immunotherapy of N-803(IL-15 superagonist)and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice[J].J Immunother Cancer,2021,9(7):e002267.
[16] ZAJC A E,CZARNECKA A M,RUTKOWSKI P.The role of macrophages in sarcoma tumor microenvironment and treatment[J].Cancers,2023,15(21):5294.
[17] CHIM L K,WILLIAMS I L,BASHOR C J,et al.Tumor-associated macrophages induce inflammation and drug resistance in a mechanically tunable engineered model of osteosarcoma[J].Biomaterials,2023,296:122076.
[18] 杨秀英,王芳,郝强,等.信号传导及转录活化因子3和Jagged1在骨肉瘤组织的表达及其临床意义[J].中华实验外科杂志,2021,38(12):2515-2517.
[19] YANG S,WANG B,LIU C,et al.THAP9-AS1 promotes tumorigenesis and reduces ROS generation through the JAK2/STAT3 signaling pathway by increasing SOCS3 promoter methylation in osteosarcoma[J].Oxid Med Cell Longev,2021:5620475.
[20] XIONG M,WANG L,YU H L,et al.Ginkgetin exerts growth inhibitory and apoptotic effects on osteosarcoma cells through inhibition of STAT3 and activation of caspase-3/9[J].Oncol Rep,2016,35(2):1034-1040.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目(82474545,82274559,81904231)
中国博士后科学基金项目(2024T170247,2024M750820)
湖北省自然科学基金项目(2024AFB1011)
武汉市自然科学基金探索计划(晨光计划)项目(2024040801020366)
△通信作者 E-mail:pufeifei@hust.edu.cn
更新日期/Last Update: 2025-02-15